Back to News
Market Impact: 0.2
Pyxis Oncology Consensus Price Target Increased by 16.92% to $8.61
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Pyxis Oncology was raised 16.92% to $8.61 per share from $7.37 as of August 25, 2026. The upward revision signals improved analyst expectations for the biotech company, though the article provides no operating, clinical, or financial catalyst behind the change.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PYXS0.40
More News
- Tech giants need legacy businesses to keep growing as they pour trillions into the AI buildout
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Evercore ISI cuts Reddit stock rating on user growth concerns
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Automate Equity Research Workflows: A Control-First Guide
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience